[1]何海涛,王智翔,张小弟,等.趋化因子配体13在肝细胞癌组织中的表达及与临床病理特征和预后关系[J].陕西医学杂志,2021,50(2):236-240.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.028]
　HE Haitao,WANG Zhixiang,ZHANG Xiaodi,et al.Expression of CXCL13 in hepatocellular carcinoma and its correlation with clinicopathological features and prognosis[J].,2021,50(2):236-240.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.028]
点击复制

趋化因子配体13在肝细胞癌组织中的表达及与临床病理特征和预后关系
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年2期
页码:
236-240
栏目:
临床病理
出版日期:
2021-02-05

文章信息/Info

Title:
Expression of CXCL13 in hepatocellular carcinoma and its correlation with clinicopathological features and prognosis
作者:
何海涛1; 王智翔2 ; 张小弟2; 沈乃营2; 张 毅2
(1.西安医学院,陕西 西安710068; 2.西安医学院附属陕西省核工业二一五医院普外科,陕西 咸阳 712000)
Author(s):
HE Haitao; WANG Zhixiang; ZHANG Xiaodi; SHEN Naiying; ZHANG Yi
(Xi'an Medical University,Xi'an 710068,China)
关键词:
趋化因子配体13;  肝细胞癌;  肿瘤微环境;  临床病理特征;  预后;  复发
Keywords:
Chemokine ligand 13;  Hepatocellular carcinoma;  Tumor microenvironment;  Clinicopathological feature;  Prognosis;  Recurrence
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7377.2021.02.028
文献标志码:
A
摘要:
目的:探讨趋化因子配体13(CXCL13)在肝细胞癌(HCC)组织中的表达及与临床病理特征和预后的关系。方法:利用免疫组织化学方法检测CXCL13在111例HCC患者术后癌组织和相应癌旁组织标本中的表达情况,分析HCC患者临床病理特征、预后及术后复发的相关性。结果:HCC中CXCL13的阳性表达明显高于相应癌旁组织(P<0.01),CXCL13在有血管浸润的组织中阳性表达率明显高于无血管浸润的组织(P=0.031),在TNM分期中Ⅲ+Ⅳ期的阳性表达率明显高于I+Ⅱ期(P=0.026)。单因素分析结果显示:甲胎蛋白、血管浸润、TNM分期、癌组织CXCL13表达是肝细胞癌的预后相关因素(P<0.01); 多因素回归分析表明:甲胎蛋白(P=0.001)、癌组织CXCL13表达(P=0.005)是肝癌患者独立预后相关因素; Kaplan-Meier生存曲线分析结果显示:CXCL13阴性表达组总生存时间和无复发生存时间优于阳性表达组(P=0.0023、0.0085)。结论:CXCL13在HCC组织中高表达并与肿瘤的浸润性生长和TNM分期密切相关,其可作为HCC患者治疗效果和预后评估的一项重要指标。
Abstract:
Objective:To investigate the expression of CXCL13 in hepatocellular carcinoma(HCC)and its correlation with clinicopathological features and prognosis.Methods:Immunohistochemical method was used to detect the expression of CXCL13 in postoperative cancer tissues and corresponding paracancerous tissue specimens of 111 HCC patients,and the correlation between the clinicopathological features,prognosis and postoperative recurrence of HCC patients was analyzed.Results:The positive expression of CXCL13 in HCC was significantly higher than that in paracancerous tissues(P<0.01).The positive expression rate of CXCL13 in vascular infiltrated tissues was significantly higher than that in non-vascular infiltrated tissues(P=0.031),and the positive expression rate of stage Ⅲ+Ⅳ in TNM stage was significantly higher than that in stage Ⅰ+Ⅱ(P=0.026).Univariate analysis showed that alpha-fetoprotein,vascular invasion,TNM staging,and CXCL13 expression in cancer tissues were the prognostic factors related to HCC(all P<0.01).Multivariate regression analysis showed that alpha-fetoprotein(P=0.001)and CXCL13 expression in cancer tissues(P=0.005)were independent prognostic factors in HCC patients.Kaplan-Meier survival curve analysis showed that the overall survival time and relapse-free survival time of the CXCL13 negative expression group were better than those of the positive expression group(P=0.0023,0.0085).Conclusion:The high expression of CXCL13 in HCC tissues is closely related to invasive tumor growth and TNM stage,which can be used as an important indicator for the treatment effect and prognosis of HCC patients.

参考文献/References:

[1] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].临床肝胆病杂志,2020,36(2):277-292.
[2] 郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析[J].陕西医学杂志,2019,48(7):850-852.
[3] 董智琦,文国容,庹必光.趋化因子及其受体在肿瘤发生发展中作用的研究进展[J].安徽医药,2018,22(6):1011-1014.
[4] 陈 霞,张国尊,刘莹莹,等.巨噬细胞与肝癌转移及临床预后关系研究[J].陕西医学杂志,2018,47(3):292-294,298.
[5] Susek KH,Karvouni M,Alici E,et al.The role of CXC chemokine receptors 1-4 on immune cells in the tumor microenvironment[J].Front Immunol,2018,9:2159.
[6] Chen X,Chen R,Jin R,et al.The role of CXCL chemokine family in the development and progression of gastric cancer[J].Int J Clin Exp Pathol,2020,13(3):484-492.
[7] Li X,Zhong Q,Luo D,et al.The prognostic value of CXC subfamily ligands in stage Ⅰ-Ⅲ patients with colorectal cancer[J].PLoS One,2019,14(4):214611.
[8] Xu TB,Ruan HL,Song ZS,et al.Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis[J].Biomedicine & Pharmacotherapy,2019,118:109264.
[9] Sorrentino C,Ciummo SL,Cipollone G,et al.Interleukin-30/IL-27p28 shapes prostate cancer stem-like cell behavior and is critical for tumor onset and metastasization[J].Cancer Research,2018,78(10):2654-2668.
[10] 肖 岚,朱 宏,张 婷,等.董克礼教授治疗原发性肝癌临床经验[J].陕西中医,2020,41(11):1639-1642.
[11] Kazanietz MG,Durando M,Cooke M.CXCL13 and its receptor CXCR5 in cancer:Inflammation,immune response,and beyond[J].Front Endocrinol(Lausanne),2019,10:471.
[12] Muzammal H,Dickson A,Muqddas T,et al.CXCL13/CXCR5 signaling axis in cancer[J].Life Sciences,2019,227:175-186.
[13] Ohandjo AQ,Liu Z,Dammer EB,et al.Transcriptome network analysis identifies CXCL13-CXCR5 signaling modules in the prostate tumor immune microenvironment[J].Sci Rep,2019,9(1):14963.
[14] Chunyan L,Dong K,Xiguang S,et al.The effect of C-X-C Motif chemokine 13 on hepatocellular carcinoma associates with wnt signaling[J].Biomed Research International,2015,2015:1-8.
[15] Duan Z,Gao J,Zhang L,et al.Phenotype and function of CXCR5+CD45RA-CD4+T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis[J].Oncotarget,2015,6(42):44239-44253.
[16] 曾 灏,翚 缨,吴志懂,等.原发性肝癌患者血清CXCL13表达水平及临床意义[J].国际检验医学杂志,2018,39(13):1557-1561.
[17] Zhang GL,Luo X,Zhang W,et al.CXCL-13 regulates resistance to 5-fluorouracil in colorectal cancer[J].Cancer Research and Treatment:Official Journal of Korean Cancer Association,2019,52(2):622-633.
[18] Alcaraz-Sanabria A,Baliu-Piqué M,Saiz-Ladera C,et al.Genomic signatures of immune activation predict outcome in advanced stages of ovarian cancer and basal-like breast tumors[J].Front Oncol,2020,9:1486.
[19] Evangelia R,Konstantine TK,Ioannis K,et al.The role of CXCL13 and CXCL9 in early breast cancer[J].Clinical Breast Cancer,2020,20(1):36-53.
[20] Xing J,Zhang C,Yang X,et al.CXCR5+CD8+ T cells infiltrate the colorectal tumors and nearby lymph nodes,and are associated with enhanced IgG response in B cells[J].Exp Cell Res,2017,356:57-63.
[21] Ryuma T,Madiha N,Jae HL,et al.B cell and B cell-related pathways for novel cancer treatments[J].Cancer Treatment Reviews,2018,73:10-19.
[22] 李延领,周英发.慢性乙型病毒性肝炎患者血清CXCL-13与IL-1β、IL-6表达及意义[J].中华实验和临床病毒学杂志,2019,33(4):372-375.

相似文献/References:

[1]刘冬宇,白 劼,白红艳.肝细胞癌组织中Foxp3+调节性T淋巴细胞表达水平及其与肿瘤免疫相关性研究[J].陕西医学杂志,2021,50(8):1019.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.029]
　LIU Dongyu,BAI Jie,BAI Hongyan.Expression level of Foxp3+regulatory T-lymphocyte in hepatocellular carcinoma and its correlation with tumor immunity[J].,2021,50(2):1019.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.029]
[2]黄丽银,斯 韬,梁 婷,等.丙酮酸脱氢酶激酶4在肝细胞癌中的作用研究进展[J].陕西医学杂志,2023,52(7):934.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.036]
　HUANG Liyin,SI Tao,LIANG Ting,et al.Research progress on role of pyruvate dehydrogenase kinase 4 in hepatocellular carcinoma[J].,2023,52(2):934.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.036]
[3]廖莹莹,张荣臻,舒发明,等.硒在慢性肝病中的作用研究进展[J].陕西医学杂志,2023,52(12):1782.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.034]
　LIAO Yingying,ZHANG Rongzhen,SHU Faming,et al.Research progress on role of selenium in chronic liver disease[J].,2023,52(2):1782.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.034]

备注/Memo

备注/Memo:
基金项目:陕西省咸阳市科学技术研究发展计划项目(2019K02-108)
更新日期/Last Update: 2021-01-28